International Health Management Associates, Inc., Schaumburg, IL, 60173, USA; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, R3E 0J9, Canada.
International Health Management Associates, Inc., Schaumburg, IL, 60173, USA.
Diagn Microbiol Infect Dis. 2020 Apr;96(4):114925. doi: 10.1016/j.diagmicrobio.2019.114925. Epub 2019 Nov 15.
The Clinical and Laboratory Standards Institute (CLSI)-defined broth microdilution testing method (M07, 11th edition, 2018) was used to determine MICs for ceftolozane/tazobactam and eight comparator agents against 21,952 isolates of Enterobacteriaceae submitted by 161 clinical laboratories in 51 countries in 2016 as a part of the SMART global surveillance program. MICs were interpreted using CLSI breakpoints (M100 29th edition, 2019). 89.7% of isolates of Enterobacteriaceae were susceptible to ceftolozane/tazobactam, compared to 70.0%, 76.3%, 77.7%, 84.7%, 93.6%, and 96.4%, respectively, for ceftriaxone, ceftazidime, cefepime, piperacillin-tazobactam, ertapenem, and meropenem. 82.4% of isolates of ESBL-positive, carbapenemase-negative Enterobacteriaceae were susceptible to ceftolozane/tazobactam, compared to 1.5%, 7.8%, 20.3%, 71.1%, 94.7%, and 98.7%, respectively, for ceftriaxone, cefepime, ceftazidime, piperacillin-tazobactam, ertapenem, and meropenem. In vitro susceptibility to ceftolozane/tazobactam was >60% higher than susceptibility to other advanced-generation cephalosporins among all Enterobacteriaceae and >10% higher than susceptibility to piperacillin-tazobactam among ESBL-positive Enterobacteriaceae collected globally in 2016.
采用临床和实验室标准协会（CLSI）定义的肉汤微量稀释检测方法（M07，第 11 版，2018 年），测定了 2016 年来自 51 个国家的 161 个临床实验室提交的 21952 株肠杆菌科分离株对头孢洛扎/他唑巴坦和 8 种比较剂的 MIC。使用 CLSI 折点（M100，第 29 版，2019 年）来解释 MIC。与头孢曲松、头孢他啶、头孢吡肟、哌拉西林/他唑巴坦、厄他培南和美罗培南相比，89.7%的肠杆菌科分离株对头孢洛扎/他唑巴坦敏感，分别为 70.0%、76.3%、77.7%、84.7%、93.6%和 96.4%。82.4%的产 ESBL、耐碳青霉烯肠杆菌科分离株对头孢洛扎/他唑巴坦敏感，分别为 1.5%、7.8%、20.3%、71.1%、94.7%和 98.7%。与其他第三代头孢菌素相比，头孢洛扎/他唑巴坦对所有肠杆菌科的体外药敏率高出>60%，与产 ESBL 肠杆菌科的哌拉西林/他唑巴坦相比高出>10%。
